Update on treatment of inclusion body myositis

Current Rheumatology Reports

Volumn 15, Issue 5, 2013, Pages

  Breithaupt, Maren ^a   Schmidt, Jens ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alemtuzumab; Dysphagia; Glucocorticosteroids; IBM; Immunosuppressants; Inclusion body myositis; Inflammatory myopathy; Intravenous immunoglobulin; Myositis; Oxandrolone; Physical training; Treatment

Indexed keywords

ADENOVIRUS VECTOR; ALEMTUZUMAB; ARIMOCLOMOL; ASCORBIC ACID; AZATHIOPRINE; BETA1A INTERFERON; BOTULINUM TOXIN A; CREATINE KINASE; CYCLOSPORIN A; ETANERCEPT; FOLLISTATIN; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LITHIUM; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXANDROLONE; PLACEBO; PREDNISONE; SIMVASTATIN; TACROLIMUS; THYMOCYTE ANTIBODY; AMYLOID; MONOCLONAL ANTIBODY;

AEROBIC CAPACITY; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASSISTIVE TECHNOLOGY DEVICE; CREATINE KINASE BLOOD LEVEL; CRICOPHARYNGEUS MUSCLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; FUNCTIONAL STATUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; LOWER ESOPHAGUS SPHINCTER; MUSCLE ATROPHY; MUSCLE NECROSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOTOMY; NONHUMAN; PHYSIOTHERAPY; PLASMAPHERESIS; RESISTANCE TRAINING; VIRAL GENE THERAPY; AMYLOIDOSIS; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REVIEW; SKELETAL MUSCLE; TREATMENT FAILURE; COMPLICATION; MYOSITIS, INCLUSION BODY; PROCEDURES;

AMYLOID; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL, HUMANIZED; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; OXANDROLONE; PHYSICAL THERAPY MODALITIES; TREATMENT FAILURE;

EID: 84875162170     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0329-z     Document Type: Article

References (46)

1. Dalakas MC. Sporadic inclusion body myositis - diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2008;2(8):437-47.
2. Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol. 2009;19(3):493-506.
3. Schmidt J, Dalakas MC. Inclusion-body myositis in the elderly: an update. Aging Health. 2010;6(6):687-94.
4. Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immnosuppressive therapy. Medicine (Baltimore). 1993;72(4):224-35.
5. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med. 1993;94(4):379-87. (Pubitemid 23106624)
6. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother. 2009;10(7):1183-90.
7. Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995;45(7):1302-4.
8. Badrising UA, Maat-Schieman ML, Ferrari MC, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol. 2002;51(3):369-72. (Pubitemid 34206293)
9. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol. 1992;19(9):1385-9.
10. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003;61(2):260-2. (Pubitemid 36875317)
11. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci. 2001;185(2):199-22. (Pubitemid 32318516)
12. Chaudhry V, Cornblath DR, Griffin JW, et al. Myocophenolate mofetil: a safe and promising immunosuppressant in neuromuscular disease. Neurology. 2001;56(1):94-6. (Pubitemid 32059658)
13. Quartuccio L, De Marchi G, Scott CA, et al. Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol. 2007;25(2):246-51. (Pubitemid 46851428)
14. Kelly Jr JJ, Madoc-Jones H, Adelman LS, et al. Total body irradiation not effective in inclusion body myositis. Neurology. 1986;36(9):1264-6. (Pubitemid 16047014)
15. Dau PC. Leukocytapharesis in inclusion body myositis. J Clin Apher. 1987;3(3):167-70. (Pubitemid 17031841)
16. Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology. 2001;57(9):1566-70.
17. Muscle Study Group. Randomized pilot trial of high-dose betaINF1a in patients with inclusion body myositis. Neurology. 2004;63(4):718-20.
18. Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology. 2006;66(2 Suppl 1):S123-4.
19. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;43(5):876-9. (Pubitemid 23150554)
20. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48(3):712-6. (Pubitemid 27120112)
21. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58(2):326.
22. Walter MC, Lochmüller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247(1):22-8. (Pubitemid 30162508)
23. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56(3):323-7. (Pubitemid 32144142)
24. • Dobloug C, Walle-Hansen R, Gran JT, Molberg O. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol. 2012;30(6); 838-42. This study provides data of long-term treatment with immunoglobulin in patients with IBM.
25. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536-44.
26. •• Beneviste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11): 3176-84. Data on the natural course of IBM were obtained in a large patient cohort.
27. •• Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11);3167-75. Data on the natural course of IBM were obtained in a large patient cohort.
28. Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trail of oxandrolone in inclusion body myositis. Neurology. 2002;58(7):1081-7. (Pubitemid 34298550)
29. • Sancricca C, Mora M, Ricci E, et al. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci. 2011;32(5): 841-7. This is an interesting study with a non-immunosuppressant.
30. Yamada T, Minohara M, Imaiso Y, et al. High-dose vitamin C therapy for inclusion body myositis. Fukuoka Igaku Zasshi. 2001;92(4):99-104.
31. •• Alexanderson H, Lundberg IE. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opinion Rheumatol. 2012;24(2): 201-7. This review gives a thorough overview of the literature and published data on exercise and physical training in inflammatory myopathies and evaluates the overall safety and efficacy.
32. Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve. 1997;20(1):1242-8. (Pubitemid 27415512)
33. Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med. 2003;35(1):31-5. (Pubitemid 36204070)
34. Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10(4):178-84.
35. Gualano B, Ugrinowitsch C, Neves M Jr. et al. Vascular occlusion training for inclusion body myositis: a novel therapeutic approach. J Vis Exp. 2010;5;(40).
36. Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87(11):883-9. This is a helpful overview on dysphagia in IBM.
37. Malandraki GA, Kaufman A, Hind J, et al. The effects of lingual intervention in a patient with inclusion body myositis and Sjögren's syndrome: a longitudinal case study. Arch Phys Med Rehabil. 2012;93(8):1469-75.
38. Murata KY, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with Dysphagia. Clin Med Insights Case Rep. 2013;6:1-7.
39. Riminton DS, Chambers ST, Parkin PJ, et al. Inclusion body myositis presenting solely as dysphagia. Neurology. 1993;43(6):1241-3. (Pubitemid 23177733)
40. Darrow DH, Hoffman HT, Barnes GJ, Willey CA. Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg. 1992;118(3):313-7.
41. Verma A, Bradley WG, Adesina AM, et al. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve. 1991;14(5):470-3.
42. Wintzen AR, Bots GT, de Bakker HM, et al. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51(12):1542-5. (Pubitemid 19026527)
43. Liu LW, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol. 2004;18(6):397-9. (Pubitemid 39076994)
44. Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol. 2008;64(1):15-24.
45. • Zschüntzsch J, Voss J, Creus K, et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle. Arthritis Rheum. 2012;64(12): 4094-103. This study suggests that the insufficient block of NO-stress is a major reason for the lack of efficacy of prednisone and IVIG.
46. • Allenbach Y, Beneviste O, Decostre V, et al. Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscul Disord. 2012;22(11): 980-6. This study provides helpful data for the choice of appropriate outcome measures in future treatment trials on IBM.